Peptide
MGF
SaveMechano Growth Factor, a splice variant of IGF-1 (IGF-1Ec) released by mechanically stimulated muscle, proposed to activate satellite cells for muscle repair.
Quick verdict
Interesting biology linking mechanical loading to muscle repair. No human clinical trials. Extremely short half-life limits injectable utility.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Identified in mechanically loaded muscle. In-vitro data show satellite cell activation. No human pharmacokinetic or efficacy data. Half-life is minutes.
Benefits
- Satellite cell activation demonstrated in vitro
- Endogenous role in exercise-induced muscle repair
Dosage notes
No validated human dosing. Community protocols cite 100–200 mcg locally injected but this is not evidence-based.
Side effects
- Unknown in humans
- Injection-site reactions
- Theoretical IGF-related risks
Who should be cautious
No clinical data. Ultra-short half-life makes unmodified MGF impractical. Gray-market product quality is suspect.
What this page cannot tell you
Biological concept is sound but translation to injectable therapy is unvalidated. PEGylated form (PEG-MGF) attempts to address half-life.
Leaderboard scores
- Muscle20
- Recovery20
Write a review
Sign in to write a review.